IP Library Granted Patent US 9,017,680
Granted Patent B2
US 9,017,680 · App. 14/542,529 · Granted Apr 28, 2015

Methods of administering anti-TNFα antibodies

Inventors: Steven A. Fischkoff (Short Hills, NJ); Joachim Kempeni (Neustadt, DE); Roberta Weiss (Wynnewood, PA)
Assignee: AbbVie Biotechnology Ltd.
C07K16/241C07K2317/565C07K2317/21C07K2317/76A61K2039/505A61K2039/545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,680
App. No.
14/542,529
Granted
Apr 28, 2015
Kind
B2
Abstract

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

Claims (7)

1. A method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising:

administering to said patient, in combination with methotrexate, a human anti-TNFα antibody,

wherein the human anti-TNFα antibody is administered subcutaneously in a total body dose of 40 mg once every 13-15 days, and

wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“V L ”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“V H ”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.

2. The method of claim 1 , wherein the V L chain region of the anti-TNFα antibody has the amino acid sequence of SEQ ID NO:1 and the V H chain region of the anti-TNFα antibody has the amino acid sequence of SEQ ID NO:2.

3. The method of claim 1 , wherein the dosage is administered from a 40 mg dosage unit form.

4. The method of claim 3 , wherein the V L chain region of the anti-TNFα antibody has the amino acid sequence of SEQ ID NO:1 and the V H chain region of the anti-TNFα antibody has the amino acid sequence of SEQ ID NO:2.

Assignments (2)
CHANGE OF NAME Recorded Feb 27, 2015
From: ABBOTT BIOTECHNOLOGY LTD.
To: ABBVIE BIOTECHNOLOGY LTD
Reel/Frame 035054/0916 →
CORRECTIVE ASSIGNMENT TO CORRECT THE DATE OF ASSIGNMENT EFFECTIVE NUNC PRO TUNC TO OCTOBER 31, 2001 PREVIOUSLY RECORDED AT REEL: 013997 FRAME: 0780. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 18, 2015
From: FISCHKOFF, STEVEN A.; WEISS, ROBERTA; KEMPENI, JOACHIM
To: ABBOTT BIOTECHNOLOGY LTD.
Reel/Frame 035033/0062 →
Continuity (3)
Continuation 10163657 · Jun 5, 2002
Provisional Application 60296961 · Jun 8, 2001
Related Publication 20150071939A1 · Mar 12, 2015